Last reviewed · How we verify
Institut Investigacio Sanitaria Pere Virgili — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Niacin plus laropiprant | Niacin plus laropiprant | marketed | Lipid-modifying agent combination | DP1 receptor (laropiprant component); niacin acts on GPR109A and other pathways | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Merck Sharp & Dohme LLC · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Institut Investigacio Sanitaria Pere Virgili:
- Institut Investigacio Sanitaria Pere Virgili pipeline updates — RSS
- Institut Investigacio Sanitaria Pere Virgili pipeline updates — Atom
- Institut Investigacio Sanitaria Pere Virgili pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Institut Investigacio Sanitaria Pere Virgili — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/institut-investigacio-sanitaria-pere-virgili. Accessed 2026-05-17.